August 9, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the 2004 recall of one of the company’s coronary stent systems.

August 9, 2011 — Acist Medical Systems Inc., a Bracco Group company and provider of advanced contrast injection system technology for cardiovascular angiography, announced that its’ Contrast Delivery System has been used to help diagnose and treat 10 million patients.

August 9, 2011 — The American Heart Association (AHA) 2011 annual scientific sessions will be held Nov. 12-16, in Orlando, Fla.

August 8, 2011 — Elsevier, provider of scientific, technical and medical information products and services, announced its Braunwald's Heart Disease Practice Guides App for iPad, iPhone and iPod Touch is now available on the App Store.

August 8, 2011 – Edwards Lifesciences announced the global launch of the Carpentier-Edwards Physio Tricuspid Annuloplasty Ring for the treatment of tricuspid valve insufficiency. The company received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE mark for European sales of the device.

August 8, 2011, — Cambridge Heart announced that the Freeport, Maine Fire Department has applied for a federal grant to establish firefighter screenings for sudden cardiac arrest (SCA) risk using the company’s Microvolt T-Wave Alternans (MTWA) non-invasive diagnostic test.

August 5, 2011 – New software aimed at making computed tomography (CT) safer for patients estimates the radiation risk based on age, gender and size rather than using the current “one size fits all” approach. The software program, tested on more than 6,500 scans, was introduced at the 2011 Joint Meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists (COMP).

August 5, 2011 — Heart failure circulatory support system maker Thoratec Corp. announced it acquired the medical business of ventricular assist device (VAD) maker Levitronix Medical. The company developed a pediatric VAD, which is currently pending U.S. Food and Drug Administration (FDA) clearance. Levitronix was purchased in a cash payment of $110 million, as well as potential future cash earnout payments of up to $40 million.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now